Completion of the transactions announced in December 2024 relating to the amendment of the convertible bonds subscribed by an entity affiliated to Heights Capital Management, inc. (“Heights”) and the issue of a second assimilable tranche
Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement
Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine
